List of Tables
Table 1: Dermatology, Global, Epidemiology of Dermatological Disorders, 2015 15
Table 2: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Humira, 2015 26
Table 3: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Remicade, 2015 27
Table 4: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Enbrel, 2015 29
Table 5: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Stelara, 2015 30
Table 6: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Neoral, 2015 32
Table 7: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Protopic, 2015 33
Table 8: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Elidel, 2015 35
Table 9: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Elocon, 2015 35
Table 10: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Differin, 2015 36
Table 11: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Metolate, 2015 37
Table 12: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Clobex, 2015 38
Table 13: Dermatology Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($bn), 2015–2022 63
Table 14: Dermatology, Global, Usage of Generics Across Key Indications, 2015 65
Table 15: Dermatology Therapeutics Market, Global, Forecast Revenue by Company, 2015–2022 72
Table 16: Dermatology Therapeutics Market, Global, Licensing Deals, 2006–2016 100
Table 17: Dermatology Therapeutics Market, Global, Co-development Deals, 2006–2016 105
Table 18: Epidemiology Patterns for Atopic Dermatitis, 2015–2022 111
Table 19: Epidemiology Patterns for Acne Vulgaris, 2015–2022 111
Table 20: Epidemiology Patterns for Psoriasis, 2015–2022 111
Table 21: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 112
Table 22: Abbreviations 144